Myasthenia Gravis Treatment : From Old Drugs to Innovative Therapies with a Glimpse into the Future
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG..
Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80-90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). In addition, considering the autoimmune basis of MG, standard therapy includes immunomodulating agents, such as corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide. New strategies have been proposed for the treatment of MG and include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). The aim of this review is to provide a detailed overview of the pre- and post-marketing evidence on the five pharmacological treatments most recently approved for the treatment of MG, by identifying both preclinical and clinical studies registered in clinicaltrials.gov. A description of the molecules currently under evaluation for the treatment of MG is also provided.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
CNS drugs - 38(2024), 1 vom: 11. Jan., Seite 15-32 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crisafulli, Salvatore [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetylcholinesterase |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 19.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s40263-023-01059-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367031027 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367031027 | ||
| 003 | DE-627 | ||
| 005 | 20240419232224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40263-023-01059-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM367031027 | ||
| 035 | |a (NLM)38212553 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crisafulli, Salvatore |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myasthenia Gravis Treatment |b From Old Drugs to Innovative Therapies with a Glimpse into the Future |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG. | ||
| 520 | |a Myasthenia gravis (MG) is a rare autoimmune disease that causes debilitating muscle weakness due to impaired neuromuscular transmission. Since most (about 80-90%) MG patients present autoantibodies against the acetylcholine receptor, standard medical therapy consists of symptomatic treatment with acetylcholinesterase inhibitors (e.g., pyridostigmine). In addition, considering the autoimmune basis of MG, standard therapy includes immunomodulating agents, such as corticosteroids, azathioprine, cyclosporine A, and cyclophosphamide. New strategies have been proposed for the treatment of MG and include complement blockade (i.e., eculizumab, ravulizumab, and zilucoplan) and neonatal Fc receptor antagonism (i.e., efgartigimod and rozanolixizumab). The aim of this review is to provide a detailed overview of the pre- and post-marketing evidence on the five pharmacological treatments most recently approved for the treatment of MG, by identifying both preclinical and clinical studies registered in clinicaltrials.gov. A description of the molecules currently under evaluation for the treatment of MG is also provided | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Acetylcholinesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.1.7 |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Receptors, Cholinergic |2 NLM | |
| 700 | 1 | |a Boccanegra, Brigida |e verfasserin |4 aut | |
| 700 | 1 | |a Carollo, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Bottani, Emanuela |e verfasserin |4 aut | |
| 700 | 1 | |a Mantuano, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Trifirò, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a De Luca, Annamaria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t CNS drugs |d 1994 |g 38(2024), 1 vom: 11. Jan., Seite 15-32 |w (DE-627)NLM09374627X |x 1179-1934 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g number:1 |g day:11 |g month:01 |g pages:15-32 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40263-023-01059-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |e 1 |b 11 |c 01 |h 15-32 | ||